Related Experiment Video
Updated: Sep 24, 2026

Harvesting Murine Alveolar Macrophages and Evaluating Cellular Activation Induced by Polyanhydride Nanoparticles
Published on: June 8, 2012
Polymyxin B prevents lipopolysaccharide-induced release of tumor necrosis factor-alpha from alveolar macrophages
D C Stokes1, J L Shenep, M Fishman
1Cardiopulmonary Division, St. Jude Children's Research Hospital, Memphis, TN 38101-0318.
Abstract:
Polymyxin B (PmB) blocks many of the toxic effects of lipopolysaccharide by mechanisms that are not yet understood. The production of tumor necrosis factor-alpha (TNF-alpha) by isolated rat alveolar macrophages in response to lipopolysaccharide and macrophage-activating factor was blocked by PmB at concentrations of 100, 10, and 1 micrograms/ml. Gentamicin enhanced rather than inhibited TNF production at the 100-micrograms/ml concentrations and had no effect at low concentration. Similar inhibitory effects were induced by PmB in an in vivo model in which rat macrophage TNF production was stimulated by intratracheally injected lipopolysaccharide. Because many of the effects of lipopolysaccharide are mediated by TNF, this inhibition provides a mechanism to explain the protection afforded by PmB against lipopolysaccharide-induced toxicity.
Insights
Polymyxin B effectively blocks toxic lipopolysaccharide effects by inhibiting tumor necrosis factor-alpha (TNF-alpha) production in macrophages. This mechanism explains Polymyxin B
Area of Science:
- Immunology
- Pharmacology
Background:
- Lipopolysaccharide (LPS) triggers toxic effects mediated by inflammatory cytokines.
- The precise mechanisms by which Polymyxin B (PmB) counteracts LPS toxicity are not fully elucidated.
Purpose of the Study:
- To investigate the effect of Polymyxin B on tumor necrosis factor-alpha (TNF-alpha) production by macrophages.
- To elucidate the role of TNF-alpha inhibition in the protective effects of PmB against LPS.
Main Methods:
- In vitro studies using isolated rat alveolar macrophages stimulated with LPS.
- In vivo studies using a rat model with intratracheal LPS administration.
- Assessment of TNF-alpha production in response to LPS and PmB treatment.
Main Results:
- Polymyxin B significantly inhibited TNF-alpha production in both in vitro and in vivo models.
- Gentamicin, an alternative antibiotic, enhanced TNF-alpha production at high concentrations.
- PmB demonstrated inhibitory effects across a range of concentrations (100, 10, and 1 µg/ml).
Conclusions:
- Polymyxin B inhibits LPS-induced TNF-alpha production.
- Inhibition of TNF-alpha is a key mechanism explaining PmB's protective effects against LPS toxicity.
Related Concept Videos
Drugs that Stabilize Microtubules
Inhibitors of Gram-positive Cell Wall Synthesis

